medigraphic.com
ISSN 1561-3186 (Electronic)

2022, Number 1

<< Back Next >>

Rev Acta Médica 2022; 23 (1)

Six-minute walk test in patients with pulmonary hypertension

Echarte MJC, Hechavarría PS, Hernández GS, González DLR

Language: Spanish
References: 29
Page:
PDF size: 200.64 Kb.


ABSTRACT

Introduction: The purpose of the six-minute walk test is to measure the maximum distance that an individual can travel during a six-minute period by walking as fast as possible.
Objective: To determine the current recommendations, applications and usefulness of the six-minute walk test in order to standardize its performance in the context of pulmonary hypertension.
Methods: The literature on the methodology, indications and application of the six-minute walk test was reviewed. A total of 63 bibliographic sources were selected, of which 29 were cited in the article.
Results: The six-minute walk test allows to know the evolution, as well as to assess the response to different treatments and establish a prognosis in patients with pulmonary hypertension.
Conclusions: The six-minute walk test is a feasible method in patients with pulmonary hypertension, and allows establishing response to treatment and prognostic scales in the management of the entity.


REFERENCES

  1. Solway S, Brooks D, Lacasse Y, Thomas S. A qualitative systematic overview of the measurement properties of functional walk tests used in the cardiorespiratory domain. Chest. 2001;119(1):256-70. DOI: http://doi.org/10.1378/chest.119.1.256

  2. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161(2):487-92. DOI: http://doi.org/10.1164/ajrccm.161.2.9906015

  3. Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7. DOI: http://doi.org/10.1164/ajrccm.166.1.at1102

  4. Holland AE, Spruit MA, Troosters T, Puhan M, Pepin V, Saey D, et al. An official European Respiratory Society/American Thoracic Society technical standard: field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1428-46. DOI: http://dx.doi.org/10.1183/09031936.00150314

  5. Singh SJ, Puhan MA, Andrianopoulos V, Hernández N, Mitchell K, Hill CJ, et al. An official systematic review of the European espiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447-78. DOI: http://dx.doi.org/10.1183/09031936.00150414

  6. Watz H, Pitta F, Rochester C, García J, Wallack R, Troosters T, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J. 2014;44(6):1521-37. DOI: https://doi.org/10.1183/09031936.00046814

  7. Benza RL, Miller DP, Gomberg-Maitland M. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122(2):164-72. DOI: https://doi.org/10.1161/CIRCULATIONAHA.109.898122

  8. Holland A, Knapman L, Brazzale DJ. The 6-minute walk test elicits high but submaximal cardiorespiratory responses in interstitial lung disease. Am J Respir Crit Care Med. 2010;181:A2968. DOI: https://doi.org/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A2968

  9. Deboeck G, Niset G, Vachiery JL, Moraine JJ, Naeije R. Physiological response to the six-minute walk test in pulmonary arterial hypertension. Eur Respir J. 2005;26(4):667-72. DOI: http://doi.org/10.1183/09031936.05.00031505

  10. McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013;62(Suppl 25):51-9. DOI: http://doi.org/10.1016/j.jacc.2013.10.03

  11. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary Rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2006;(4):CDOO3793. DOI: http://doi.org/10.1002/14651858.CD003793.pub2

  12. Puhan M, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary Rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;(1):CDOO5305. DOI: http://dx.doi.org/101002/14651858.CDOO5305

  13. Holland A, Hill C. Physical training for interstitial lung disease. Cochrane Database Syst Rev. 2008;(4):CDOO6322. DOI: http://doi.org/10.1002/14651858.CD006322.pub2

  14. Gochicoa Rangel L, Mora Romero U, Guerrero Zúñiga S, Silva Cerón M, Cid Juárez S, Velázquez Uncal M, et al. Prueba de caminata de 6 minutos. Recomendaciones y procedimientos. Neumol Cir Torax. 2015 [acceso: 16/09/2021];74(2):127-36. Disponible en: http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0028-37462015000200008

  15. Barón O, Díaz G. Caminata de los seis minutos, propuesta de estandarización del protocolo y aplicación práctica para la evaluación de la hipertensión pulmonar con especial referencia a la de los niños. Rev Colomb Cardiol. 2016;23(1):59-67. DOI: http://dx.doi.org/10.1016/j.rccar.2015.05.011

  16. Ridruejo R, Serrano P, Pascual I, Suárez MA, Zalba B, Tarancón C. El test de la marcha de los seis minutos en hipertensión pulmonar de cualquier etiología. Arch Med. 2009;5(3):1. DOI: http://doi.org/doi.org/10.3823/029

  17. López J, Montes de Oca M, Ortega Balza M, Lezama J. Enfermedad pulmonar obstructiva crónica. Evaluación de la tolerancia al ejercicio utilizando tres tipos diferentes de pruebas de esfuerzo. Arch Bronconeumol. 2001;37:69-74. DOI: http://doi.org/10.1016/S0300-2896(01)75017-X

  18. Galiè N, Torbicki A, Barst R. Guías de práctica clínica sobre el diagnóstico y el tratamiento de la hipertensión arterial pulmonar. Rev Esp Cardiol. 2005;58:523-66. http://doi.org/10.1157/13074846

  19. Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxigen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17(4):647-52. DOI: http://doi.org/10.1183/09031936.01.17406470

  20. Escribano P, Gómez MA, Jiménez C, Ruiz MJ. Evidencia científica en hipertensión pulmonar. Manual de actuación. Arch Med. 2009 [acceso: 16/09/2021];5(3):1. Disponible en: https://dialnet.unirioja.es/descarga/articulo/3262604.pdf

  21. Wensel R, Opitz CF, Ander SD, Winkler J, Hoffken G, Kleber FX, et al. Assessments of survival in patients with primary pulmonary hipertensión: importance of cardiopulmonary exercise testing. Circulation. 2002;106(3):319-24. DOI: http://doi.org/10.1161/01.CIR.0000022687.18568.2A

  22. Humbert M, Sitbon O, Chaocuat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary Arterial Hypertension in France. Results from a National Registry. Am J Respir Crit Care Med. 2006;173(9):1023-30. DOI: http://doi.org/10.1164/rccm.200510-1668OC

  23. Zagolin M, Wainstein GE, Polentzi Uriarte G, Parra C. Caracterización clínica, funcional y hemodinámica de la población con hipertensión pulmonar arterial evaluada en el Instituto Nacional del Tórax. Rev Med Chile. 2006;134(5):589-95. DOI: http://dx.doi.org/10.4067/S0034-98872006000500007

  24. Enright P, Sherrill D. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med. 1998;58(5):1384-7. DOI: http://doi.org/10.1164/ajrccm.158.5.9710086

  25. Thenappan T, Shah SJ, Rich S, Gomberg-Maitland M. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007;30:1103-10. DOI: https://doi.org/10.1183/09031936.00042107

  26. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106(12):1477-82. DOI: http://doi.org/10.1161/01.cir.0000029100.82385.58

  27. McLaughlin VV, Presberg KW, Doyle RL, Abman S, McCrory D, Fortin T, et al. Prognosis of Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines. Chest. 2004;126:78S-92S. DOI: http://doi.org/10.1378/chest.126.1_suppl.78S

  28. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC) International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119. DOI: http://doi.org/10.1093/eurheartj/ehv317

  29. Savarese G, Paolillo S, Costanzo P, D’Amore C, Cecere M, Losco T, et al. Do Changes of 6-minute walk distance predict clinical events in patients with Pulmonary Arterial Hypertension? A Meta-Analysis of 22 Randomized Trials. J Am Col Cardiol. 2012;60(13):1192-201. DOI: http://dx.doi.org/10.1016/j.jacc.2012.01.083




2020     |     www.medigraphic.com